MicroRNAs as therapeutic targets in atherosclerosis

Bibliography

• Caro CG. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29(2):158-61
   PubMed Web of Science ®Google Scholar
• Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009;6(1):16-26
   PubMedGoogle Scholar
• Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006;86(2):515-81
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. Origins and mechanisms of miRNAs and siRNAs. Cell 2009;136(4):642-55
   PubMed Web of Science ®Google Scholar
• van Rooij E, Olson EN. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 2007;117(9):2369-76
   PubMed Web of Science ®Google Scholar
• Olson EN. MicroRNAs as therapeutic targets and biomarkers of cardiovascular disease. Sci Transl Med 2014;6(239):239ps3
   PubMed Web of Science ®Google Scholar
• Ait-Oufella H, Sage AP, Mallat Z, et al. Adaptive (T and B cells) immunity and control by dendritic cells in atherosclerosis. Circ Res 2014;114(10):1640-60
   PubMed Web of Science ®Google Scholar
• Garcia-Cardena G, Comander J, Anderson KR, et al. Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc Natl Acad Sci USA 2001;98(8):4478-85
   PubMed Web of Science ®Google Scholar
• Kumar S, Kim CW, Simmons RD, et al. Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol 2014;34(10):2206-16
   PubMed Web of Science ®Google Scholar
• Loyer X, Potteaux S, Vion AC, et al. Inhibition of microRNA-92a prevents endothelial dysfunction and atherosclerosis in mice. Circ Res 2014;114(3):434-43
   PubMed Web of Science ®Google Scholar
• Fang Y, Shi C, Manduchi E, et al. MicroRNA-10a regulation of proinflammatory phenotype in athero-susceptible endothelium in vivo and in vitro. Proc Natl Acad Sci USA 2010;107(30):13450-5
   PubMed Web of Science ®Google Scholar
• Hergenreider E, Heydt S, Treguer K, et al. Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 2012;14(3):249-56
   PubMed Web of Science ®Google Scholar
• Kohlstedt K, Trouvain C, Boettger T, et al. AMP-activated protein kinase regulates endothelial cell angiotensin-converting enzyme expression via p53 and the post-transcriptional regulation of microRNA-143/145. Circ Res 2013;112(8):1150-8
   PubMed Web of Science ®Google Scholar
• Qin X, Wang X, Wang Y, et al. MicroRNA-19a mediates the suppressive effect of laminar flow on cyclin D1 expression in human umbilical vein endothelial cells. Proc Natl Acad Sci USA 2010;107(7):3240-4
   PubMed Web of Science ®Google Scholar
• Wang KC, Garmire LX, Young A, et al. Role of microRNA-23b in flow-regulation of Rb phosphorylation and endothelial cell growth. Proc Natl Acad Sci USA 2010;107(7):3234-9
   PubMed Web of Science ®Google Scholar
• Wu W, Xiao H, Laguna-Fernandez A, et al. Flow-dependent regulation of kruppel-like factor 2 is mediated by microRNA-92a. Circulation 2011;124(5):633-41
   PubMed Web of Science ®Google Scholar
• Fang Y, Davies PF. Site-specific microRNA-92a regulation of Kruppel-like factors 4 and 2 in atherosusceptible endothelium. Arterioscler Thromb Vasc Biol 2012;32(4):979-87
   PubMed Web of Science ®Google Scholar
• Son DJ, Kumar S, Takabe W, et al. The atypical mechanosensitive microRNA-712 derived from pre-ribosomal RNA induces endothelial inflammation and atherosclerosis. Nat Commun 2013;4:3000
   PubMed Web of Science ®Google Scholar
• Zhou J, Wang KC, Wu W, et al. MicroRNA-21 targets peroxisome proliferators-activated receptor-alpha in an autoregulatory loop to modulate flow-induced endothelial inflammation. Proc Natl Acad Sci USA 2011;108(25):10355-60
   PubMed Web of Science ®Google Scholar
• Weber M, Baker MB, Moore JP, et al. MiR-21 is induced in endothelial cells by shear stress and modulates apoptosis and eNOS activity. Biochem Biophys Res Commun 2010;393(4):643-8
   PubMed Web of Science ®Google Scholar
• Wang S, Aurora AB, Johnson BA, et al. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15(2):261-71
   PubMed Web of Science ®Google Scholar
• Schober A, Nazari-Jahantigh M, Wei Y, et al. MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1. Nat Med 2014;20(4):368-76
   PubMed Web of Science ®Google Scholar
• Zhou J, Li YS, Nguyen P, et al. Regulation of vascular smooth muscle cell turnover by endothelial cell-secreted microRNA-126: role of shear stress. Circ Res 2013;113(1):40-51
   PubMed Web of Science ®Google Scholar
• Zernecke A, Bidzhekov K, Noels H, et al. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2(100):81
   Web of Science ®Google Scholar
• Sun X, Icli B, Wara AK, et al. MicroRNA-181b regulates NF-kappaB-mediated vascular inflammation. J Clin Invest 2012;122(6):1973-90
   PubMed Web of Science ®Google Scholar
• Sun X, He S, Wara AK, et al. Systemic delivery of microRNA-181b inhibits nuclear factor-kappaB activation, vascular inflammation, and atherosclerosis in apolipoprotein E-deficient mice. Circ Res 2014;114(1):32-40
   PubMed Web of Science ®Google Scholar
• Cheng HS, Sivachandran N, Lau A, et al. MicroRNA-146 represses endothelial activation by inhibiting pro-inflammatory pathways. EMBO Mol Med 2013;5(7):949-66
   PubMed Web of Science ®Google Scholar
• Li P, Zhu N, Yi B, et al. MicroRNA-663 regulates human vascular smooth muscle cell phenotypic switch and vascular neointimal formation. Circ Res 2013;113(10):1117-27
   PubMed Web of Science ®Google Scholar
• Xin M, Small EM, Sutherland LB, et al. MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury. Genes Dev 2009;23(18):2166-78
   PubMed Web of Science ®Google Scholar
• Lovren F, Pan Y, Quan A, et al. MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation 2012;126(11 Suppl 1):S81-90
   Web of Science ®Google Scholar
• Sala F, Aranda JF, Rotllan N, et al. MiR-143/145 deficiency protects against progression of atherosclerosis in Ldlr-/-mice. Thromb Haemost 2014;112(4):796-802
   PubMed Web of Science ®Google Scholar
• O’Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10(2):111-22
   PubMed Web of Science ®Google Scholar
• Zernecke A. MicroRNAs in the regulation of immune cell functions–implications for atherosclerotic vascular disease. Thromb Haemost 2012;107(4):626-33
   PubMed Web of Science ®Google Scholar
• Lee KS, Kim J, Kwak SN, et al. Functional role of NF-kappaB in expression of human endothelial nitric oxide synthase. Biochem Biophys Res Commun 2014;448(1):101-7
   PubMed Web of Science ®Google Scholar
• Nazari-Jahantigh M, Wei Y, Noels H, et al. MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest 2012;122(11):4190-202
   PubMed Web of Science ®Google Scholar
• Du F, Yu F, Wang Y, et al. MicroRNA-155 deficiency results in decreased macrophage inflammation and attenuated atherogenesis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2014;34(4):759-67
   PubMed Web of Science ®Google Scholar
• Donners MM, Wolfs IM, Stoger LJ, et al. Hematopoietic miR155 deficiency enhances atherosclerosis and decreases plaque stability in hyperlipidemic mice. PLoS One 2012;7(4):e35877
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen T, Yang L, et al. Regulation of microRNA-155 in atherosclerotic inflammatory responses by targeting MAP3K10. PLoS One 2012;7(11):e46551
   Web of Science ®Google Scholar
• Wei Y, Nazari-Jahantigh M, Chan L, et al. The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis. Circulation 2013;127(15):1609-19
   PubMed Web of Science ®Google Scholar
• Androulidaki A, Iliopoulos D, Arranz A, et al. The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 2009;31(2):220-31
   PubMed Web of Science ®Google Scholar
• Di Gregoli K, Jenkins N, Salter R, et al. MicroRNA-24 Regulates Macrophage Behavior and Retards Atherosclerosis. Arterioscler Thromb Vasc Biol 2014;34(9):1990-2000
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328(5985):1570-3
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Sheedy FJ, Esau CC, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121(7):2921-31
   PubMed Web of Science ®Google Scholar
• Rotllan N, Ramirez CM, Aryal B, et al. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice–brief report. Arterioscler Thromb Vasc Biol 2013;33(8):1973-7
   PubMed Web of Science ®Google Scholar
• Marquart TJ, Wu J, Lusis AJ, et al. Anti-miR-33 therapy does not alter the progression of atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 2013;33(3):455-8
   PubMed Web of Science ®Google Scholar
• Horie T, Baba O, Kuwabara Y, et al. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc 2012;1(6):e003376
   PubMed Web of Science ®Google Scholar
• Loyer X, Vion AC, Tedgui A, et al. Microvesicles as cell-cell messengers in cardiovascular diseases. Circ Res 2014;114(2):345-53
   PubMed Web of Science ®Google Scholar
• Rayner KJ, Esau CC, Hussain FN, et al. Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. Nature 2011;478(7369):404-7
   PubMed Web of Science ®Google Scholar
• Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013;368(18):1685-94
   PubMed Web of Science ®Google Scholar
• van der Ree MH, van der Meer AJ, de Bruijne J, et al. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res 2014;111:53-9
   PubMed Web of Science ®Google Scholar
• van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov 2012;11(11):860-72
   PubMed Web of Science ®Google Scholar